HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating for Arrowhead Pharma (NASDAQ:ARWR) and maintained a price target of $60.
September 03, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Arrowhead Pharma, maintaining a $60 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $60 price target by a reputable analyst firm suggests a positive outlook for Arrowhead Pharma, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100